Genetic Variants Associated with Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results from the Treatment of Early Aggressive Rheumatoid Arthritis Trial

Methotrexate (MTX) has emerged as first-line therapy for early moderate to severe rheumatoid arthritis (RA), but individual variation in treatment response remains unexplained. We tested the associations between 863 known pharmacogenetic variants and MTX response in 471 TEAR Trial participants with...

Descripción completa

Detalles Bibliográficos
Autores principales: Aslibekyan, Stella, Brown, Elizabeth E., Reynolds, Richard J., Redden, David T., Morgan, Sarah, Baggott, Joseph, Sha, Jin, Moreland, Larry W., O’Dell, James R., Curtis, Jeffrey R., Mikuls, Ted R., Bridges, S. Louis, Arnett, Donna K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701736/
https://www.ncbi.nlm.nih.gov/pubmed/23545897
http://dx.doi.org/10.1038/tpj.2013.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701736/
https://www.ncbi.nlm.nih.gov/pubmed/23545897
http://dx.doi.org/10.1038/tpj.2013.11

Ejemplares similares